FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT). Abstract #1128

Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Aim(s): Investigated the role of FDG PET as a prognostic factor P-NET treated with Lu-PRRT.
Materials and methods: A total of 65 G1-G2 P-NET patients (pts), with documented radiological progression, were treated with 2 different activities of 18.5 GBq or 27.8 GBq according to the pts’s kidney function and bone marrow reserve. 31 received a total activity (TA) of 27.8 GBq and 34 a TA of 18.5GBq. TA was divided into 5 cycles, 6-8 weeks apart. 56 of 65 pts underwent a FDG PET before Lu-PRRT.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
Keywords: PRRT, FDG-PET, P-NET
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico
#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT
Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Lisa Bodei
Authors: Bodei L, Kidd M, Singh A, Severi S, ...
Keywords: PRRT, efficacy
#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT